Endometrial cancer (EMC) is a sex steroid hormone-related female malignancy. Androgen and androgen receptor (androgen/AR) signals have been implicated in EMC progression. Cancer stem/progenitor cells (CSPCs) are suspected to link to chemoresistance in patients with EMC. In this study, we examined the androgen/AR roles in cisplatin resistance and CSPC population. We found AR expression increased naive EMC side population, CSPC population, cell migration, and epithelial–mesenchymal transition. Meanwhile, it decreased cisplatin cytotoxic effect on EMC cells. Collaterally, endogenous AR expressions in EMC cells were upregulated in the cisplatin-resisting state. Moreover, AR expression could further enhance CD133 expression, CSPC-related markers, and drug-resistance gene messenger RNA expression in EMC cells. Finally, the AR-associated gene expression might go through indirect regulation. This is the first report revealing AR function on EMC cells’ CSPC and cisplatin resistance.
American Cancer Society. Cancer Facts & Figures2012. Atlanta, GA: American Cancer Society; 2012.
2.
AroraVQuinnMA. Endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2012;26(3):311–324.
3.
WrightJDBarrena MedelNISehouliJFujiwaraKHerzogTJ. Contemporary management of endometrial cancer. Lancet. 2012;379(9823):1352–1360.
4.
PiergaJYDierasVParaisoDPouillartP.Chemotherapy of metastatic endometrial carcinoma. Review of the literature. Bull Cancer. 1995;82(12):1005–1018.
5.
VermorkenJBHoekmanK. Chemotherapy for gynecologic malignancies. Curr Opin Oncol. 1995;7(5):457–465.
6.
NakamuraMKyoSZhangBPrognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol. 2010;41(11):1516–1529.
7.
RutellaSBonannoGProcoliACells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res. 2009;15(13):4299–4311.
8.
RahadianiNIkedaJMamatSExpression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer Sci. 2011;102(4):903–908.
9.
ChangCSKokontisJLiaoST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science. 1988;240(4850):324–326.
10.
YehSTsaiMYXuQGeneration and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA. 2002;99(21):13498–13503.
11.
HuYCWangPHYehSSubfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci USA. 2004;101(31):11209–11214.
12.
LegroRSKunselmanARMillerSASatyaswaroopPG. Role of androgens in the growth of endometrial carcinoma: an in vivo animal model. Am J Obstet Gynecol. 2001;184(3):303–308.
13.
Koivisto-KoranderRButzowRKoivistoAMLeminenA. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumour Biol. 2011;32(3):451–459.
14.
RodriguezGBilbaoCRamirezRAlleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer. Int J Cancer. 2006;118(6):1420–1425.
15.
DizonDSTejada-BergesTKoellikerSSteinhoffMGranaiCO. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest. 2006;62(4):226–228.
16.
JohnsonSMMaleki-DizajiMStylesJAWhiteIN. Ishikawa cells exhibit differential gene expression profiles in response to oestradiol or 4-hydroxytamoxifen. Endocr Relat Cancer. 2007;14(2):337–350.
17.
YehSLinHKKangHYThinTHLinMFChangC. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA. 1999;96(10):5458–5463.
18.
MaWLHsuCLYehCCHepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology. 2012;56(1):176–185.
19.
PetrizJ. Flow cytometry of the side population (SP). Curr Protoc Cytom. 2007;Chapter 9:Unit9.23.
20.
LiHQiYLiCAngiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther. 2009;8(12):3255–3265.
21.
InoueMKyoSFujitaMEnomotoTKondohG. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 1994;54(11):3049–3053.
22.
HonigAWeidlerCHauslerSOverexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. Anticancer Res. 2010;30(5):1559–1564.
23.
HubbardSAFrielAMKumarBZhangLRuedaBRGargettCE. Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res. 2009;69(21):8241–8248.
24.
MakVCSiuMKWongOGChanKKNganHYCheungAN. Dysregulated stemness-related genes in gynecological malignancies. Histol Histopathol. 2012;27(9):1121–1130.
25.
KristiansenGDenkertCSchlunsKDahlEPilarskyCHauptmannS. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol. 2002;161(4):1215–1221.
26.
HubbardSAGargettCE. A cancer stem cell origin for human endometrial carcinoma?Reproduction. 2010;140(1):23–32.
27.
LakhaniNJVenitzJFiggWDSparreboomA. Pharmacogenetics of estrogen metabolism and transport in relation to cancer. Curr Drug Metab. 2003;4(6):505–513.
28.
KishabaYMatsubaraDNikiT. Heterogeneous expression of nestin in myofibroblasts of various human tissues. Pathol Int. 2010;60(5):378–385.
29.
LiZHuSWangJMiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010;119(1):125–130.
30.
Fukunaga-KalabisMMartinezGNguyenTKTenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene. 2010;29(46):6115–6124.
31.
McAuliffeSMMorganSLWyantGATargeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA. 2012;109(43):E2939–E2948.
32.
MaWLHsuCLWuMHAndrogen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology. 2008;135(3):947–955, 955.e941–955.e945.
33.
FerrettiVPoitrasCBergeronDCoulombeBRobertFBlanchetteM. PReMod: a database of genome-wide mammalian cis-regulatory module predictions. Nucleic Acids Res. 2007;35(Database issue):D122–D126.
34.
SusumuNSagaeSUdagawaYRandomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(1):226–233.
35.
KyoSMaidaYInoueM. Stem cells in endometrium and endometrial cancer: accumulating evidence and unresolved questions. Cancer Lett. 2011;308(2):123–133.
36.
BonkhoffHRembergerK. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate. 1996;28(2):98–106.
37.
BarclayWWAxanovaLSChenWCharacterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells. 2008;26(3):600–610.
38.
LeeSOMaZYehCRNew therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol. 2013;5(1):14–26.
39.
XinLLukacsRULawsonDAChengDWitteON. Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells. 2007;25(11):2760–2769.
40.
Abou-KheirWGHynesPGMartinPLPierceRKellyK. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten−/−TP53−/− prostate cancer model. Stem Cells. 2010;28(12):2129–2140.
41.
GermannMWetterwaldAGuzman-RamirezNStem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells. 2012;30(6):1076–1086.
42.
CaiHMemarzadehSStoyanovaTBeharryZKraftASWitteON. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res. 2012;72(18):4672–4681.
43.
HuangCKLeeSOLaiKPTargeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. Hepatology. 2013;57(4):1550–1563.
SinghRArtazaJNTaylorWEGonzalez-CadavidNFBhasinS. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003;144(11):5081–5088.
46.
ChangCYHsuuwYDHuangFJAndrogenic and antiandrogenic effects and expression of androgen receptor in mouse embryonic stem cells. Fertil Steril. 2006;85(suppl 1):1195–1203.
47.
ClaustresMSultanC. Stimulatory effects of androgens on normal children's bone marrow in culture: effects on BFU-E, CFU-E, and uroporphyrinogen I synthase activity. Horm Res. 1986;23(2):91–98.
48.
SullivanPSJacksonCWMcDonaldTP. Castration decreases thrombocytopoiesis and testosterone restores platelet production in castrated BALB/c mice: evidence that testosterone acts on a bipotential hematopoietic precursor cell. J Lab Clin Med. 1995;125(3):326–333.
49.
ViselliSMReeseKRFanJKovacsWJOlsenNJ. Androgens alter B cell development in normal male mice. Cell Immunol. 1997;182(2):99–104.
50.
ErbenRGEberleJStangassingerM. B lymphopoiesis is upregulated after orchiectomy and is correlated with estradiol but not testosterone serum levels in aged male rats. Horm Metab Res. 2001;33(8):491–498.
51.
BrannvallKBogdanovicNKorhonenL, Lindholm D. 19-Nortestosterone influences neural stem cell proliferation and neurogenesis in the rat brain. Eur J Neurosci. 2005;21(4):871–878.
52.
YangHPGarcia-ClosasMLaceyJVJrGenetic variation in the androgen receptor gene and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18(2):585–589.
53.
JuWKimSC. Polymorphisms in CAG active allele length of the androgen receptor gene are not associated with increased risk of endometrial cancer. Cancer Genet Cytogenet. 2007;172(2):178–179.
54.
PignataSScambiaGPisanoCA multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007;96(11):1639–1643.
55.
GadducciACosioSGenazzaniAR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol. 2006;58(3):242–256.
56.
Egawa-TakataTUedaYKuragakiCChemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy. Cancer Chemother Pharmacol. 2011;68(6):1603–1610.
57.
HorieKTakakuraKImaiKLiaoSMoriT. Immunohistochemical localization of androgen receptor in the human endometrium, decidua, placenta and pathological conditions of the endometrium. Hum Reprod. 1992;7(10):1461–1466.
58.
FujimotoJNishigakiMHoriMIchigoSItohTTamayaT. The effect of estrogen and androgen on androgen receptors and mRNA levels in uterine leiomyoma, myometrium and endometrium of human subjects. J Steroid Biochem Mol Biol. 1994;50(3-4):137–143.
59.
MinoricsRBozsityNWolflingJAntiproliferative effect of normal and 13-epi-D-homoestrone and their 3-methyl ethers on human reproductive cancer cell lines. J Steroid Biochem Mol Biol. 2012;132(1-2):168–175.
60.
ChonHSMarchionDCXiongYThe BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol. 2012;124(1):119–124.
61.
ChenHLibertiniSJGeorgeMGenome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer. 2010;17(4):857–873.
62.
MoutsatsouPSekerisCE. Steroid receptors in the uterus: implications in endometriosis. Ann N Y Acad Sci. 2003;997:209–222.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
